A critical evaluation of methods for preparing pentavalent 99tcm-dmsa

Nuclear Medicine Communications

Volumn 20, Issue 8, 1999, Pages 769-774

  Leah, M ^a   Williams, E D ^a,b  

^a UNIVERSITY OF SUNDERLAND   (United Kingdom)

^b SUNDERLAND ROYAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SUCCIMER TC 99M;

AMYLOIDOSIS; ARTICLE; DIAGNOSTIC VALUE; DRUG DETERMINATION; DRUG FORMULATION; DRUG INDICATION; OSTEOSARCOMA; SOFT TISSUE TUMOR; THYROID MEDULLARY CARCINOMA;

DRUG CONTAMINATION; EVALUATION STUDIES; HUMANS; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M DIMERCAPTOSUCCINIC ACID;

EID: 0032749737     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1080/00006231-199908000-00012     Document Type: Article

References (7)

1. Blower P, Singh J, Clarke SEM. The chemical identity of pentavelent technetium-99m-dimercaptosuccinic acid. J Nucl Med 1991; 32: 845-849.
2. Ohta H, Yamamoto K, Endo K et al. A new imaging agent for medullary carcinoma of the thyroid. J Nucl Med 1984; 25: 323-325.
3. Clarke SEM, Lazarus CR, Wraight P et al. Pentavalent 99mTc-DMSA, 131I-MIBG, 99mTc-MDP: An evaluation of three imaging techniques in patients with medullary carcinoma of the thyroid. J Nucl Med 1988; 29: 33-38.
4. Kobayashi H, Sakahara H, Hosono Metal. Soft-tissue tumor diagnosis with Tc-99m (V) dimercaptosuccinic acid scintigraphy. Radiology 1994; 190: 277-280.
5. Addenbrooke’s Hospital, Cambridge. Radiopharmacy handbook, 1st edn. London: UK Radiopharmacy Group, 1997: 32.
6. Birmingham City Hospital. Radiopharmacy handbook, 1st edn. London: UK Radiopharmacy Group, 1997: 33.
7. Hirano T, Tomiyoshi K, Zhang YJ, Ishida T, Inoue T, Endo K. Preparation and clinical evaluation of technetium-99m dimercaptosuccinic acid for tumour scintigraphy. Eur J Nucl Med 1994; 21: 82-85.